Jiangsu Cancer Hospital in Nanjing is a large provincial cancer centre and a frequent lead site for Chinese oesophageal, lung and gastric cancer trials.
Jiangsu Cancer Hospital in Nanjing, also known as the Jiangsu Institute of Cancer Research and the Affiliated Cancer Hospital of Nanjing Medical University, is a large provincial cancer centre and a frequent lead site for Chinese oesophageal, lung and gastric cancer trials. It has high oesophageal and lung cancer volumes, hosts domestic PD-1, antibody-drug conjugate and radiotherapy trials, and runs the province's screening programmes in one of China's oesophageal cancer high-incidence regions. OnCo connects it to oesophageal cancer, non-small-cell lung cancer and gastric cancer. How much of its trial activity produces evidence that regulators outside China accept is the open question for centres of this kind. Its oesophageal, thoracic and screening programmes are listed below.
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-15.
Matched to Jiangsu Cancer Hospital, including child institutions. 503 works · 5,684 citations · 75% open access · 18% clinical trials · 2% reviews.
Shares Oesophageal cancer and the tag china.
Shares Oesophageal cancer and the tag china.
Shares Gastric & gastro-oesophageal junction cancer and the tag china.
Shares Gastric & gastro-oesophageal junction cancer and the tag china.
Shares Oesophageal cancer and the tag china.
Shares Gastric & gastro-oesophageal junction cancer and the tag china.
Shares Non-small-cell lung cancer and the tag china.
Shares Non-small-cell lung cancer and the tag china.